SEARCH:   Advanced

Blood, 9 April 2009, Vol. 113, No. 15, pp. 3604-3611. Prepublished online as a Blood First Edition Paper on February 3, 2009; DOI 10.1182/blood-2008-08-175323. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-08-175323v1 113/15/3604    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pulsipher, M. A. Articles by Confer, D. L. Search for Related Content PubMed PubMed Citation Articles by Pulsipher, M. A. Articles by Confer, D. L. Related Collections Transfusion Medicine Transplantation Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSFUSION MEDICINE Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program Michael A. Pulsipher1, Pintip Chitphakdithai2, John P. Miller3, Brent R. Logan4, Roberta J. King2, J. Douglas Rizzo4, Susan F. Leitman5, Paolo Anderlini6, Michael D. Haagenson2, Seira Kurian7, John P. Klein4, Mary M. Horowitz4, and Dennis L. Confer3 1 University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City; 2 Center for International Blood and Marrow Transplant Research (CIBMTR), Minneapolis, MN; 3 National Marrow Donor Program, Minneapolis, MN; 4 CIBMTR, Medical College of Wisconsin, Milwaukee; 5 Clinical Center, National Institutes of Health, Bethesda, MD; 6 University of Texas M. D. Anderson Cancer Center, Houston; and 7 Los Angeles County Department of Public Health, CA Limited data are available describing donor adverse events (AEs) associated with filgrastim mobilized peripheral blood stem cell (PBSC) collections in unrelated volunteers. We report results in 2408 unrelated PBSC donors prospectively evaluated by the National Marrow Donor Program (NMDP) between 1999 and 2004. Female donors had higher rates of AEs, requiring central line placement more often (17% vs 4%, P < .001), experiencing more apheresis-related AEs (20% vs 7%, P < .001), more bone pain (odds ratio [OR] = 1.49), and higher rates of grades II-IV and III-IV CALGB AEs (OR = 2.22 and 2.32). Obese donors experienced more bone pain (obese vs normal, OR = 1.73) and heavy donors had higher rates of CALGB toxicities (> 95 kg vs < 70 kg, OR = 1.49). Six percent of donors experienced grade III-IV CALGB toxicities and 0.6% experienced toxicities that were considered serious and unexpected. Complete recovery is universal, however, and no late AEs attributable to donation have been identified. In conclusion, PBSC collection in unrelated donors is generally safe, but nearly all donors will experience bone pain, 1 in 4 will have significant headache, nausea, or citrate toxicity, and a small percentage will experience serious short-term adverse events. In addition, women and larger donors are at higher risk for donation-related AEs. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020